Slide 1: Myriad Genetics First Quarter 2022 Earnings
Myriad Genetics First Quarter 2022 Earnings May 5, 2022
Slide 2: Forward looking statements
Forward looking statements Some of the information These statements are based on management’s current expectations and the actual presented here today may events or results may differ materially and adversely from these expectations. We contain projections or refer you to the documents the Company f
Slide 3: Who we are, what we do, and why it matters
Who we are, what we do, and why it matters Illuminating the path to better health through genetic insights. Our purpose-led Mission We advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us. Our Vision As a leader in genetic testing and precision
Slide 4: Empowering patients with answers and insights for better health
Empowering patients with answers and insights for better health “ At Myriad Genetics, our mission is to advance health and well-being for all, empowering patients to take control of their health and enabling healthcare providers to better detect, treat and prevent disease. For more than 30 years, we
Slide 5: First quarter operating and financial highlights
First quarter operating and financial highlights 1 2 3 4 5 Total revenue of Diagnostic test GAAP total operating GAAP operating loss Diluted GAAP EPS of $164.9 million volumes of 241,000 expenses were in the quarter was $(0.26) improved increased 11% increased 10% YoY $142.5 million; $25.6 million;
Slide 6: Strategic priorities
Strategic priorities A trusted, differentiated partner with specialized expertise Innovation that improves clinical Enterprise capabilities to accelerate Focus on execution and delivery of outcomes, ease of use, and access growth and scale to market opportunity consistent results Developing and enha
Slide 7: Expanded Precise Tumor partnership with Intermountain Precision Genomics
Expanded Precise Tumor partnership with Intermountain Precision Genomics to accelerate launch of liquid biopsy therapy selection (LBTS) test offering Sample • Sales & marketing of LBTS • Expands Precise™ Oncology Solutions • Validates LBTS test (Illumina TSO500 ctDNA • Sample collection & accessioni
Slide 8: In-house Measurable Residual Disease (MRD) solution
In-house Measurable Residual Disease (MRD) solution built upon Myriad Genetics' existing core competencies Current status: Expected performance: • Prototype underway; pharma availability expected in ’23 • High sensitivity, high specificity, and fast turnaround time • Protocols for clinical studies u
Slide 9: Nicole Lambert, Chief Operating Officer
Nicole Lambert, Chief Operating Officer
Slide 10: Mental Health
Mental Health Using genetic insights to help physicians understand Quarterly highlights how genetic alterations • GeneSight volumes in the first quarter reach one of its highest levels ever impact patient response to • GeneSight Psychotropic 4.1 launches antidepressants and other with key updates in
Slide 11: Women's Health
Women’s Health Leading health and Quarterly highlights wellness with best-in- • MyRisk with RiskScore remains the only test of its kind for women of all class genetic insights for ancestries women of all ancestries, • Launched new Virtual Care Solution in assessing cancer risk Women’s partnership wi
Slide 12: Oncology
Oncology Clarifying cancer Quarterly highlights treatment with genetic • Successful March 2022 launch of Precise Tumor for molecular tumor Designed to help providers insights and companion profiling determine the best treatment diagnostic tests that • New partnership with Intermountain Women’s plans
Slide 13: Bryan Riggsbee, Chief Financial Officer
Bryan Riggsbee, Chief Financial Officer
Slide 14: Financial highlights: Revenue and test volume
Myriad continues to stabilize business and improve operating and financial results Financial highlights • Maintained both GAAP & adjusted gross margins • Improved GAAP loss per share by $0.26 and within guidance adjusted loss per share by $0.03 compared to • Stable ASP results for 7 consecutive quar
Slide 15: Consolidated quarterly highlights
Consolidated quarterly highlights Revenue excluding divested assets, adjusted gross margin, adjusted operating income, adjusted EPS Quarter ended *In millions March 2022 December 2021 March 2021 Revenue* $164.6 $160.8 $148.4 Annual change 11% 19% — Adjusted gross margin 71.1% 71.8% 71.5% Annual chan
Slide 16: First quarter 2022 revenue by product, excluding divested assets
First quarter 2022 — revenue by product, excluding divested assets Three months ended March 31, 2022 2021 In millions Women’s Oncology Mental Total Women’s Oncology Mental Total % Change Health Health Health Health Hereditary cancer $33.6 $37.3 — $70.9 $31.5 $44.6 — $76.1 (7%) Prenatal 31.9 — — 31.9
Slide 17: First quarter 2022 revenue and test performance
First quarter 2022 revenue and test performance Year over Year % Sequential % Revenue Test Volume Revenue Test Volume Hereditary cancer (7%) (12%) (5%) (10%) Prenatal 35% (1%) 6% 3% Tumor profiling 5% 12% 23% 17% Pharmacogenomics 66% 49% 0% 7% Overall company (5%) (3%) 3% 2% Overall company 11% 10%
Slide 18: Myriad strengths and strategic advantages
Myriad strengths and strategic advantages Significant market growth in focused business areas Leader in genetic testing and precision medicine Industry • Successfully implementing transformation and leading Best-in-class growth strategy operating product quality margins & • Broad and growing commerc
Slide 19: Myriad Genetics Health. Illuminated.
Myriad genetics Health. Illuminated.
Slide 20: Thank you
Thank you ©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com